Trials / Completed
CompletedNCT00097422
OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)
An Open-Label, Dose Ranging, Randomized Clinical Evaluation of OPT-80 in Patients With Clostridium Difficile-Associated Diarrhea (CDAD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the safety and perform preliminary clinical evaluation in patients with mild to moderate CDAD.
Detailed description
This is a dose-finding study to select a safe and efficacious dose of OPT-80. Patients will be evaluated for safety and efficacy and pharmacokinetic parameters will be investigated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OPT-80 |
Timeline
- Start date
- 2004-11-01
- Primary completion
- 2005-04-01
- Completion
- 2005-04-01
- First posted
- 2004-11-24
- Last updated
- 2017-03-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00097422. Inclusion in this directory is not an endorsement.